Discover 447 paid clinical trials in Edmonton, . Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Edmonton has a research history that most cities cannot match: the first successful islet cell transplant protocol for type 1 diabetes, known worldwide as the Edmonton Protocol, was developed at the University of Alberta in 2000 and changed transplant medicine. Diabetes studies are still a local strength, alongside cancer research at the Cross Cancer Institute, the comprehensive cancer centre for northern Alberta since 1968. Of the roughly 500 studies recruiting in the city, about a third are in oncology, with multiple myeloma and breast cancer among the most common, and the rest span inflammatory bowel disease, pulmonary hypertension, and sleep apnea.
Filter
2
Filter results
Results: 447
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Atrial Fibrillation Occurring Transiently With Stress
for
Stroke, Atrial Fibrillation
Location: Edmonton, Calgary, Medicine Hat, Saskatoon, Regina,
Sponsor: Population Health Research Institute
Sex: All
Age: 55+
Code: NCT03968393
Recruiting
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations